What's New
 |
GAITHERSBURG, Md., March 21, 1997 -- TreviMed(TM), a developer, manufacturer and marketer of patented DNA diagnostic kits and complementary accessories which enable healthcare professionals to identify genetic associated with diseases such as cancer, Alzheimer's, glaucoma, and sickle cell anemia, has selected Brent Burdick, PhD, to serve as the company's President.
Dr. Burdick has extensive experience in the biomedical, pharmaceutical and healthcare industries. He has an impressive track record
for enabling biotechnology companies to develop practical applications for innovative technologies. His expertise in DNA diagnostics, genetic testing, and integrated engineering will be focused on guiding TreviMed in the development of new technologies and in the commercialization of these technologies for clinical applications.
TreviMed's proprietary Mismatch Identification DNA Analysis System (MIDAS) core technology facilitates the development of rapid, economical DNA diagnostic tests for the early diagnosis and treatment of diseases, which can lead to improved clinical outcomes and reduced healthcare costs. The use of MIDAS technology is based on the findings of the human genome project, which has linked the presence of point mutations in DNA with the development of cancer and genetic diseases.
The patented TreviMed MIDAS technology simplifies the detection of DNA mutations, making it faster, more accurate, and less expensive than existing technologies such as direct DNA sequencing which is more costly and labor-intensive than MIDAS; and DNA hybridization which is complex to use and provides less specific results. MIDAS can also be used to determine a patient's DNA repair index, information which can help increase the success of chemotherapy and radiotherapy treatments for cancer.
TreviMed's research and development capacity has been strengthened by a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH), and development agreements with Georgetown University Medical Center, and the National Institute of Standards and Technology. The company is aggressively seeking investments capital to complete the development and commercialization of its proprietary molecular diagnostic technology.
More "Top of the News" stories
Just type your keywords in the space provided below, then click on the Search button.
This site is maintained by webmaster@pslgroup.com All contents Copyright (c) 1995 P\S\L Consulting Group Inc. All rights reserved.
Please contact us with any comments, problems or bugs.